These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

72 related articles for article (PubMed ID: 9870494)

  • 1. Mycophenolate mofetil in cyclosporin-associated thrombotic microangiopathy.
    Lecornu-Heuze L; Ducloux D; Rebibou JM; Martin L; Billerey C; Chalopin JM
    Nephrol Dial Transplant; 1998 Dec; 13(12):3212-3. PubMed ID: 9870494
    [No Abstract]   [Full Text] [Related]  

  • 2. Severe vital depression as the presenting feature of cyclosporin-A-associated thrombotic microangiopathy.
    van der Molen LR; van Son WJ; Tegzess AM; Stegeman CA
    Nephrol Dial Transplant; 1999 Apr; 14(4):998-1000. PubMed ID: 10328490
    [No Abstract]   [Full Text] [Related]  

  • 3. Regression of post-transplant Kaposi sarcoma after discontinuing cyclosporin and giving mycophenolate mofetil instead.
    Hussein MM; Mooij JM; Roujouleh HM
    Nephrol Dial Transplant; 2000 Jul; 15(7):1103-4. PubMed ID: 10862670
    [No Abstract]   [Full Text] [Related]  

  • 4. Use of mycophenolate mofetil in renal transplant patients with cyclosporin toxicity.
    Shaheen FA; Sheikh IA
    Transplant Proc; 1999 Dec; 31(8):3294. PubMed ID: 10616481
    [No Abstract]   [Full Text] [Related]  

  • 5. Mycophenolate mofetil in cyclosporine-associated nephrotoxicity.
    Ducloux D; Fournier V; Bresson-Vautrin C; Rebibou JM; Saint-Hillier Y; Chalopin JM
    Transplant Proc; 1998 Sep; 30(6):2825-7. PubMed ID: 9745583
    [No Abstract]   [Full Text] [Related]  

  • 6. Cyclosporine withdrawal in post-renal transplant thrombotic microangiopathy.
    Manzoor K; Ahmed E; Akhtar F; Kazi JI; Naqvi SA; Rizvi SA
    Clin Transplant; 2006; 20(1):43-7. PubMed ID: 16556152
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Chronic allograft nephropathy: effect of cyclosporine reduction and addition of mycophenolate mofetil on progression of renal disease.
    Weir MR; Fink JC; Hanes DS; Gardner J; Klassen DK; Cangro C; Schweitzer E; Bartlett ST
    Transplant Proc; 1999; 31(1-2):1286-7. PubMed ID: 10083574
    [No Abstract]   [Full Text] [Related]  

  • 8. Contribution of mycophenolate mofetil after withdrawal of cyclosporine to toxicity in kidney transplantation.
    Hazzan M; Bourdon F; Dracon M; Lelièvre G; Noël C
    Transplant Proc; 1998 Sep; 30(6):2809-10. PubMed ID: 9745575
    [No Abstract]   [Full Text] [Related]  

  • 9. Use of mycophenolate mofetil in patients with chronic cyclosporine nephrotoxicity.
    Wombolt DG; McCune TR; Stewart M
    Transplant Proc; 1998 Jun; 30(4):1194. PubMed ID: 9636483
    [No Abstract]   [Full Text] [Related]  

  • 10. Cyclosporine-associated thrombotic microangiopathy: report of two cases with good outcome and successful subsequent reuse.
    Dhib M; Moulin B; Abderrahim E; Etienne I; Godin M; Fillastre JP
    Transplant Proc; 1993 Jun; 25(3):2294-6. PubMed ID: 8516905
    [No Abstract]   [Full Text] [Related]  

  • 11. Mycophenolate mofetil as an effective alternative to cyclosporin in post-transplant haemolytic uraemic syndrome.
    Agarwal DK; Gulati S; Mehta A; Kumar A; Sharma RK; Mehta B; Gupta A; Gupta RK
    Nephrol Dial Transplant; 2000 Dec; 15(12):2064-5. PubMed ID: 11096161
    [No Abstract]   [Full Text] [Related]  

  • 12. Safety of the allopurinol-mycophenolate mofetil combination in the treatment of hyperuricemia of kidney transplant recipients.
    Navascués RA; Gómez E; Rodriguez M; Laures AS; Baltar J; Grande JA
    Nephron; 2002 May; 91(1):173-4. PubMed ID: 12021539
    [No Abstract]   [Full Text] [Related]  

  • 13. Cytomegalovirus colitis in a CMV-seropositive renal transplant recipient on triple drug therapy (including mycophenolate).
    Smak Gregoor PJ; van Gelder T; Abraham Tanis A; Chadha-Ajwani S; Klaassen RJ; Weimar W
    Nephrol Dial Transplant; 1997 Dec; 12(12):2766-7. PubMed ID: 9430894
    [No Abstract]   [Full Text] [Related]  

  • 14. Mycophenolate mofetil and cyclosporin treatment for recalcitrant pyoderma gangrenosum.
    Hohenleutner U; Mohr VD; Michel S; Landthaler M
    Lancet; 1997 Dec; 350(9093):1748. PubMed ID: 9413469
    [No Abstract]   [Full Text] [Related]  

  • 15. The role of early renal biopsy in cyclosporin induced thrombotic microangiopathy.
    Burke GA; McGraw ME; MacIver AG
    Pediatr Nephrol; 1999 Sep; 13(7):564-6. PubMed ID: 10460501
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Use of mycophenolate mofetil in patients with a transplanted kidney and cyclosporin nephrotoxicity].
    Hrvacević R; Ignjatović Lj; Vavić N; Dimitrijević J; Drasković-Pavlović B; Dujić A; Elaković D; Kronja G; Marić M
    Vojnosanit Pregl; 2001; 58(2):157-60. PubMed ID: 11475669
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Change of treatment from cyclosporin to mycophenolate mofetil in severe psoriasis.
    Davison SC; Morris-Jones R; Powles AV; Fry L
    Br J Dermatol; 2000 Aug; 143(2):405-7. PubMed ID: 10951153
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mycophenolate mofetil as an alternative to cyclosporine in post renal transplant thrombocytopenia.
    Phadke K; Bagirath A
    Pediatr Nephrol; 2004 Jul; 19(7):822-3. PubMed ID: 15141344
    [No Abstract]   [Full Text] [Related]  

  • 19. Mycophenolate mofetil substitution for cyclosporine-dependent myasthenia gravis and nephrotoxicity.
    Lim AK; Donnan G; Chambers B; Ierino FL
    Intern Med J; 2007 Jan; 37(1):55-9. PubMed ID: 17199845
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sirolimus and mycophenolate mofetil after liver transplantation.
    Kniepeiss D; Iberer F; Grasser B; Schaffellner S; Tscheliessnigg KH
    Transpl Int; 2003 Jul; 16(7):504-9. PubMed ID: 12687325
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.